• LAST PRICE
    1.8700
  • TODAY'S CHANGE (%)
    Trending Up0.2700 (16.8750%)
  • Bid / Lots
    1.8300/ 2
  • Ask / Lots
    1.8900/ 1
  • Open / Previous Close
    1.6100 / 1.6000
  • Day Range
    Low 1.6100
    High 1.9200
  • 52 Week Range
    Low 1.4300
    High 5.6500
  • Volume
    397,739
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 1.6
TimeVolumePTN
09:32 ET129281.65
09:38 ET1001.658
09:41 ET78671.6768
09:43 ET51001.61
09:48 ET4611.65
09:52 ET59801.65
09:57 ET52111.65
09:59 ET67801.65
10:03 ET1001.66
10:12 ET5001.6538
10:15 ET4501.65
10:17 ET92811.65
10:21 ET3421.665
10:30 ET1001.67
10:32 ET1001.67
10:33 ET3001.66
10:35 ET6001.6601
10:44 ET1091.6739
10:46 ET2001.6675
10:51 ET3221.6701
10:53 ET346521.73
10:55 ET2001.73
10:57 ET30001.7
11:02 ET1051.6819
11:04 ET51001.69
11:08 ET13481.72
11:09 ET147601.72
11:11 ET25821.7203
11:13 ET10001.7386
11:15 ET1001.74
11:18 ET105671.77
11:20 ET12001.77
11:22 ET39991.7501
11:24 ET14981.76
11:29 ET15031.7778
11:31 ET6301.77
11:36 ET37041.78
11:38 ET3831.7997
11:40 ET49331.81
11:42 ET4901.8
11:44 ET50921.8199
11:45 ET2801.82
11:47 ET5641.8281
11:49 ET16891.84
11:51 ET52501.84
11:54 ET20871.8599
11:56 ET17001.8512
11:58 ET194501.89
12:00 ET49931.9
12:02 ET20921.91
12:03 ET61501.92
12:05 ET12001.9
12:07 ET14001.8747
12:09 ET6271.8707
12:16 ET12501.88
12:18 ET14501.9
12:20 ET3001.88
12:21 ET3581.87
12:23 ET5001.866
12:25 ET3801.86
12:30 ET31581.85
12:34 ET30001.8508
12:36 ET13031.8357
12:38 ET8501.83
12:39 ET6001.84
12:41 ET3001.84
12:45 ET3731.84
12:52 ET1001.8491
12:54 ET12001.8469
12:56 ET5501.84
01:01 ET1001.84
01:03 ET8001.85
01:06 ET1451.8301
01:10 ET37001.86
01:12 ET5501.86
01:14 ET10001.86
01:15 ET11601.855
01:17 ET1461.8554
01:19 ET8091.85
01:21 ET1341.841
01:30 ET5121.8501
01:33 ET4001.85
01:35 ET10001.859
01:42 ET14171.84
01:46 ET54371.86
01:51 ET23401.8768
01:53 ET109011.84
01:55 ET6531.87
02:02 ET2001.87
02:08 ET9511.845
02:09 ET108831.83
02:11 ET37001.82
02:13 ET2001.82
02:22 ET1651.812
02:26 ET2001.82
02:38 ET1001.81
02:40 ET8141.82
02:42 ET9001.79
02:44 ET11271.8
02:45 ET2001.8
02:51 ET6001.8
03:02 ET1001.8099
03:03 ET6001.8
03:05 ET4901.805
03:20 ET52001.81
03:21 ET14451.82
03:23 ET103871.8399
03:30 ET4001.825
03:34 ET1001.82
03:36 ET1071.83
03:39 ET10951.83
03:41 ET11901.83
03:45 ET9611.825
03:48 ET23051.84
03:50 ET19001.8298
03:56 ET10191.82
03:57 ET40931.85
03:59 ET238461.87
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPTN
Palatin Technologies Inc
25.8M
-0.8x
---
United StatesTLIS
Talis Biomedical Corp
16.2M
-0.2x
---
United StatesLPCN
Lipocine Inc
27.3M
-1.7x
---
United StatesSYBX
Synlogic Inc
20.7M
-0.2x
---
United StatesTCRT
Alaunos Therapeutics Inc
29.8M
-0.8x
---
United StatesEVGN
Evogene Ltd
37.2M
-1.4x
---
As of 2024-03-29

Company Information

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with unmet medical need and commercial potential. Its new product development activities focus primarily on MC1r agonists, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also engaged developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. It has completed Phase III PL9643 clinical study for dry eye disease. It is also conducting Phase II study of oral PL8177 in patients with ulcerative colitis.

Contact Information

Headquarters
4B Cedar Brook DriveCRANBURY, NJ, United States 08512
Phone
609-495-2200
Fax
609-495-2202

Executives

Independent Chairman of the Board
John Prendergast
President, Chief Executive Officer, Director
Carl Spana
Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary
Stephen Wills
Independent Director
Robert deVeer
Independent Director
Alan Dunton

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$25.8M
Revenue (TTM)
$7.1M
Shares Outstanding
16.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.92
EPS
$-2.48
Book Value
$0.01
P/E Ratio
-0.8x
Price/Sales (TTM)
3.6
Price/Cash Flow (TTM)
---
Operating Margin
-324.83%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.